Patents Examined by Suzanne M. Noakes
  • Patent number: 12291707
    Abstract: The present disclosure provides gene edited modified immune cells or precursors thereof (e.g., gene edited modified T cells) comprising an exogenous T cell receptor (TCR) and/or a chimeric antigen receptor (CAR) having specificity for a target antigen, and an insertion and/or deletion in one or more endogenous gene loci, wherein the endogenous gene loci encode regulators of T cell function, thereby resulting in immune cells having enhanced function. Compositions and methods of treatment are also provided. The present invention provides methods of screening for TCR- or CAR-T cells with enhanced immune function (e.g., T cell efficacy, T cell memory, and/or T cell persistence).
    Type: Grant
    Filed: January 29, 2024
    Date of Patent: May 6, 2025
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Jiangtao Ren
  • Patent number: 12285446
    Abstract: Provided herein are methods and compositions comprising a bacterium or a metabolite thereof for enhancing mitochondrial and/or peroxisomal function.
    Type: Grant
    Filed: July 12, 2023
    Date of Patent: April 29, 2025
    Assignee: The General Hospital Corporation
    Inventors: Gary Ruvkun, J. Amaranath Govindan, Elamparithi Jayamani
  • Patent number: 12286461
    Abstract: The present invention discloses a recombinant fused polypeptide, a preparation method therefor, and use thereof. The recombinant fused polypeptide is represented by the following general formula: X-linker1-Y; Y-linker1-X; X-linker2-Y; Y-linker2-X, where X is PRCWRGEGGGGIVRRADRAAVPGGGGRGD; and Y is Acetyl-SDKPGGGGTSLDASIIWAMMQNGGGGLSKL. The recombinant fused polypeptide according to the present invention can treat various fibrosis diseases and symptoms, and therapeutic use includes anti-pulmonary fibrosis, anti-hepatic fibrosis, anti-skin fibrosis, anti-renal fibrosis, anti-myocardial fibrosis, and resistance to lung tissue lesions.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: April 29, 2025
    Assignee: NANJING ANJI BIOLOGICAL TECHNOLOGY CO., LTD.
    Inventor: Hanmei Xu
  • Patent number: 12286663
    Abstract: A gene editing system of Candida viswanathii includes a Candida viswanathii, a first gene editing fragment and a second gene editing fragment. The first gene editing fragment successively includes a first homology arm and a screening gene. The second gene editing fragment is connected to a C-terminus of the first gene editing fragment and includes a second homology arm, a Cas9 expression cassette and a sgRNA cassette. The Cas9 expression cassette successively includes a Cas9 promoter, a Cas9 gene and three nuclear localization sequences. The sgRNA cassette successively includes a sgRNA promoter, a first ribozyme, a targeting sequence, a scaffold and a second ribozyme. The first gene editing fragment and the second gene editing fragment are constructed as a linear fragment for gene editing of a chromosome of the Candida viswanathii.
    Type: Grant
    Filed: March 24, 2023
    Date of Patent: April 29, 2025
    Assignees: NATIONAL TSING HUA UNIVERSITY, Chang Chun Plastics Co., Ltd., Chang Chun Petrochemical Co., LTD., DAIREN CHEMICAL CORP.
    Inventors: Yu-Chen Hu, Nam Ngoc Pham, June-Yen Chou, Hsing-Yun Wang, Vincent Jianan Liu
  • Patent number: 12286459
    Abstract: The disclosure relates to insecticidal toxin resistance management and screening of novel insecticidal toxins. One embodiment relates to the isolation, characterization, compositions, and methods of use relating to polynucleotides encoding novel insecticidal toxin receptors and the polypeptides encoded thereby. The polynucleotides and polypeptides are useful in identifying or designing novel insecticidal toxin receptor ligands including novel insecticidal toxins.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: April 29, 2025
    Assignee: PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: Claire Marie Bazyk, Catherine J Clark, Ruth Cong, James M Hasler, Jingtong Hou, Naga Kishore Kakani, Deirdre Kapka-Kitzman, Song Leng, John P Mathis, Mark Edward Nelson, Takashi Yamamoto
  • Patent number: 12286659
    Abstract: A tandem DNA element capable of enhancing protein synthesis efficiency, in particular, the nucleic acid construct is formed by an IRES enhancer (such as ScBOI1, ScFLO8, ScNCE102, ScMSN1, KlFLO8, KlNCE102, KlMSN1, KlBOI1) derived from eukaryotic cells (such as yeast), a ? sequence, and a yeast-specific Kozak sequence in tandem. The use of the nucleic acid construct in a yeast-based in vitro biosynthesis system (such as a yeast-based in vitro protein synthesis system) can significantly improve protein synthesis efficiency.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: April 29, 2025
    Inventors: Min Guo, Zijian Zhou, Xue Yu
  • Patent number: 12275972
    Abstract: Provided are a microorganism of the genus Corynebacterium which produces a purine nucleotide, and a method of producing a purine nucleotide using the microorganism.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: April 15, 2025
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Ji Hyun Lee, Sojung Park, Hee Su Kwon, Dae Young Kim, Ji Hye Lee
  • Patent number: 12275942
    Abstract: Disclosed is a method for producing, in one step, “made to measure” double-stranded DNA vectors from molecular bricks including sequences of interest in the presence of a one and only type IIs restriction enzyme.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: April 15, 2025
    Assignees: Universite de Lille, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Geoffroy De Bettignies, Carine De Bettignies, Sylvain Julien
  • Patent number: 12275973
    Abstract: The present invention relates to a method for producing cytidine 5?-monophospho-N-acetyl-neuraminic acid (CMP-Neu5Ac, 1) from low-cost substrates N-acetyl-D-glucosamine (GlcNAc), pyruvate, cytidine and polyphosphate in a single reaction mixture with a set of optionally immobilized or optionally co-immobilized enzymes comprising N-acylglucosamine 2-epimerase (AGE), an N-acetylneuraminate lyase (NAL), an N-acylneuraminate cytidylyltransferase (CSS), a uridine kinase (UDK), a uridine monophosphate kinase and a polyphosphate kinase 3 (PPK3). Further, said process may be adapted to produce Neu5Acylated i.e. sialylated biomolecules and biomolecules including a saccharide, a peptide, a protein, a glycopeptide, a glycoprotein, a glycolipid, a glycan, an antibody, and a glycoconjugate, in particular, an antibody drug conjugate, and a carbohydrate conjugate vaccine, or a flavonoid.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: April 15, 2025
    Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.
    Inventors: Thomas F. T. Rexer, Reza Mahour
  • Patent number: 12264331
    Abstract: Engineered nucleic acids encoding genome editing system components are provided, as are engineered RNA-guided nucleases that include inserts encoded in part by cellular genomic or other sequences recognized by guide RNAs.
    Type: Grant
    Filed: May 12, 2023
    Date of Patent: April 1, 2025
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Hariharan Jayaram, Barrett Ethan Steinberg
  • Patent number: 12264342
    Abstract: This invention pertains to mutant Lachnospiraceae bacterium ND2006 (Lb) Cas12a nucleic acids and proteins for use in CRISPR/Cas12a endonuclease systems, and their methods of use. In particular, the invention pertains to an isolated mutant LbCas12a protein, wherein the isolated mutant LbCas12a protein is active in a CRISPR/Cas12a endonuclease system. The invention also includes isolated nucleic acids encoding mutant LbCas12a proteins, ribonucleoprotein complexes and CRISPR/Cas12a endonuclease systems having mutant LbCas12a proteins.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: April 1, 2025
    Assignee: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Sarah Franz Beaudoin, Michael Allen Collingwood, Christopher Anthony Vakulskas
  • Patent number: 12263208
    Abstract: The present disclosure relates to novel chimeric cell wall hydrolases with anti-Staphylococcus activity. The disclosure also relates to compositions comprising these chimeric cell wall hydrolases and uses thereof in the treatment of conditions associated with Staphylococcus sp.
    Type: Grant
    Filed: September 11, 2024
    Date of Patent: April 1, 2025
    Assignee: Topaz Biosciences, Inc.
    Inventors: Teresa Shock, Oliver Liu, Maritza Miller, Jennifer Shock
  • Patent number: 12258591
    Abstract: The invention relates to a new method of characterising a target polynucleotide. The method uses a pore and a Dda helicase. The helicase controls the movement of the target polynucleotide through the pore. The invention also relates to modified Dda helicases which can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.
    Type: Grant
    Filed: October 17, 2022
    Date of Patent: March 25, 2025
    Assignee: Oxford Nanopore Technologies PLC
    Inventors: Mark Bruce, Andrew John Heron, Ruth Moysey, Szabolcs Soeroes, Elizabeth Jayne Wallace, James White
  • Patent number: 12258557
    Abstract: A mammalian or avian cell line that expresses high levels of human influenza virus receptors is provided. In one embodiment, the cell line supports human influenza virus, e.g., human A/H3 influenza virus, isolation and growth much more effectively than corresponding conventional (unmodified) cells or in corresponding human virus receptor-overexpressing cells, and the propagated viruses may maintain higher genetic stability than in the corresponding cells.
    Type: Grant
    Filed: November 30, 2023
    Date of Patent: March 25, 2025
    Assignees: Wisconsin Alumni Research Foundation (WARF), The University of Tokyo
    Inventors: Yoshihiro Kawaoka, Kosuke Takada, Masaki Imai
  • Patent number: 12258595
    Abstract: The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are structural information on the Cas protein of the CRISPR-Cas system, use of this information in generating modified components of the CRISPR complex, vectors and vector systems which encode one or more components or modified components of a CRISPR complex, as well as methods for the design and use of such vectors and components. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system. In particular the present invention comprehends optimized functional CRISPR-Cas enzyme systems.
    Type: Grant
    Filed: December 27, 2022
    Date of Patent: March 25, 2025
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTIT JTE OF TECHNOLOGY, UNIVERSITY OF TOKYO, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Silvana Konermann, Alexandro Trevino, Mark Brigham, Fei Ran, Patrick Hsu, Chie-Yu Lin, Osamu Nureki, Hiroshi Nishimasu, Ryuichiro Ishitani, Feng Zhang
  • Patent number: 12258588
    Abstract: The present disclosure relates to fusion proteins including an iron-sulfur protein (e.g., cholesterol 7-desaturase (C7D)) and a ferredoxin reductase (e.g., KshB) that can efficiently convert cholesterol to 7-dehydrocholesterol (7-DHC) in vivo. Also disclosed herein are engineered microbes (e.g., E. coli) expressing the fusion proteins and methods of use thereof.
    Type: Grant
    Filed: October 18, 2024
    Date of Patent: March 25, 2025
    Assignee: Hangzhou Enhe Biotechnology Co., Ltd.
    Inventors: Yazhou Zu, Zhenhua Pang, Igor Walter Bogorad
  • Patent number: 12258590
    Abstract: The invention includes a mutant Taq polymerase, which can significantly extend and amplify a target sequence where the extension conditions are time limited to as little as one second. The mutant Taq polymerase, or a biologically active fragment thereof, has one or more substitutions differing from the wild type as shown in Table I.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: March 25, 2025
    Assignee: ABCLONAL SCIENCE, INC.
    Inventors: Zhenyu Zhu, Dapeng Sun
  • Patent number: 12252717
    Abstract: The invention relates to modified helicases with reduced unbinding from polynucleotides. The helicases can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.
    Type: Grant
    Filed: October 18, 2022
    Date of Patent: March 18, 2025
    Assignee: Oxford Nanopore Technologies PLC
    Inventors: Andrew John Heron, James Anthony Clarke, Ruth Moysey, Elizabeth Jayne Wallace, Mark John Bruce, Lakmal Jayasinghe, Domenico Caprotti, Szabolcs Soeroes, Luke McNeill, David Antoni Alves, Rebecca Victoria Bowen, John Milton
  • Patent number: 12252519
    Abstract: The present invention relates to crystal forms of a replication protein encoded by a plasmid isolated from a Multiple Sclerosis patient, crystal structure information obtained from them, methods of preparing such crystal forms, their use for the identification and/or design of inhibitors of said replication proteins and methods for identifying, optimizing and designing compounds which should have the ability to interact with or inhibit the replication protein.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: March 18, 2025
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
    Inventors: Timo Bund, Grant S. Hansman, Turgay Kilic, Alexander N. Popov, Ethel-Michele De Villiers-Zur Hausen, Harald Zur Hausen
  • Patent number: 12252687
    Abstract: Provided is a recombinant yeast expressing germacrene A synthetase or a fusion protein thereof, wherein the fusion protein is germacrene A synthetase and farnesyl pyrophosphate synthase. The recombinant yeast improves the yield of germacrene A, and is suitable for the industrialized production of ?-elemene and/or germacrene A.
    Type: Grant
    Filed: August 25, 2023
    Date of Patent: March 18, 2025
    Assignees: Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences
    Inventors: Xueli Zhang, Luqi Huang, Zhubo Dai, Dong Wang, Lili Zhang, Juan Guo, Yi Liu